LQDA · Liquidia Corp
$75.33
+1.00 (+1.35%)
At close · Aug 19
Market Cap
$6.95B
Shares
89.51M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$75.33
Open$74.99
Day$73.29–76.65
52W close$21.80–91.03
Avg vol 30d1.6M
Short int12.0M · 13.4% float · 8.3d
Short vol69%
Last earningsAug 12, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 8, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+54%
above
Price vs 50-day avg
−5%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
77%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−13%
trailing
6-month return
+145%
trailing
YTD return
+118%
this year
Relative strength
+133%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $79 › 200d $49 — 50d above 200d
Institutional flow
Accumulating
+35% holders QoQ · +128 funds added
Insider flow
Distributing
Net -$120.6M over 90 days · 100% sells
Short interest
Falling
13.37% of float · ▼ -3.0% MoM · 8.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
339 holders — near 3-yr high, broad support
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
+1031%
Y/Y
EPS growth
+51%
Y/Y
Free cash flow
$-40.0M
Balance sheet
$170.8M
net cash
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−36%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Net revenue
· 2027
$1B
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+54%
Bullish
Price vs 50-day avg
−5%
Neutral
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
77%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $79 › 200d $49 — 50d above 200d
Institutional flow
Accumulating
+35% holders QoQ · +128 funds added
Insider flow
Distributing
Net -$120.6M over 90 days · 100% sells
Short interest
Falling
13.37% of float · ▼ -3.0% MoM · 8.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
339 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $22
Now $75 · 77%
Range high $91
vs 200-day avg +54%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $96.3M | the second quarter of 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net income 74.72M
+3.82M Interest expense, net
+6.98M Income tax expense
+400K Depreciation and amortization
+10.37M Stock-based compensation
= Adjusted EBITDA 96.29M
|
|||
| Cash Balance | $284.2M | Q2 2026 | — |
| Net product sales | $170.4M | Q2 2026 | +2514.7% |
|
|
|||
| Net product sales annualized run-rate | $682M | Q2 2026 | — |
| Patients started on treatment since launch | 5,000 | as of July 31, 2026 | — |
| Prescribers | 1,100 | as of July 31, 2026 | — |
| Total prescribers since launch | 1,100 | as of July 31, 2026 | — |
| Unique patient prescriptions since launch | 5,900 | as of July 31, 2026 | — |
| YUTREPIA net product sales | $170.4M | the second quarter of 2026 | +2514.7% |
|
|
|||
| Patients treated since launch | 2,900 | as of February 28, 2026 | — |
| Unique prescriptions received since launch | 3,600 | as of February 28, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LQDA
this stock
Liquidia Corp
|
$6.95B | +118.4% | +1031.2% | — | 13.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.75B | +17.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$50.24B | +4.0% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.41B | -2.4% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LQDA | -4.4% | -13.5% | +144.7% | -10.4% | +118.4% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | -4.0% | -16.4% | +133.1% | -13.4% | +105.6% |
Key facts
CIK
1819576
CUSIP
53635D202
13F (30d)
313 filings
310 filers
Visit website
Investor relations